Barclays Issues Positive Forecast for BeOne Medicines (NASDAQ:ONC) Stock Price

BeOne Medicines (NASDAQ:ONC) had its target price raised by stock analysts at Barclays from $415.00 to $446.00 in a report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 9.74% from the stock’s current price.

Several other research analysts also recently commented on the stock. Truist Financial raised their price target on shares of BeOne Medicines from $418.00 to $420.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on BeOne Medicines from $425.00 to $445.00 and gave the stock an “overweight” rating in a research report on Thursday, October 1st. Nomura increased their price objective on BeOne Medicines from $454.75 to $484.91 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, TD Cowen lifted their price objective on BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $432.53.

BeOne Medicines Price Performance

Shares of ONC stock traded up $19.16 during trading hours on Friday, reaching $406.41. The stock had a trading volume of 409,739 shares, compared to its average volume of 317,660. The stock’s fifty day simple moving average is $362.80 and its 200 day simple moving average is $325.98. The firm has a market capitalization of $44.62 billion, a PE ratio of 71.66 and a beta of 0.63. BeOne Medicines has a 12 month low of $253.95 and a 12 month high of $409.80. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last posted its earnings results on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The business had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.76 billion. On average, equities research analysts predict that BeOne Medicines will post 8.99 EPS for the current year.

Insider Activity at BeOne Medicines

In related news, COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $357.87, for a total value of $41,158,986.57. Following the completion of the transaction, the chief executive officer directly owned 125,799 shares in the company, valued at approximately $45,019,688.13. This represents a 47.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 376,373 shares of company stock valued at $134,848,154 over the last ninety days. 6.19% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. raised its stake in shares of BeOne Medicines by 184.4% during the third quarter. Jefferies Financial Group Inc. now owns 18,200 shares of the company’s stock worth $6,660,000 after acquiring an additional 11,800 shares in the last quarter. Knights of Columbus Asset Advisors LLC bought a new stake in shares of BeOne Medicines in the 3rd quarter worth approximately $106,000. Allspring Global Investments Holdings LLC boosted its stake in shares of BeOne Medicines by 22.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 966 shares of the company’s stock valued at $340,000 after purchasing an additional 178 shares in the last quarter. Hager Investment Management Services LLC purchased a new stake in shares of BeOne Medicines in the 3rd quarter valued at $891,000. Finally, Ethic Inc. bought a new position in shares of BeOne Medicines during the 3rd quarter valued at $218,000. 48.55% of the stock is currently owned by institutional investors.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.